See more : PT Digital Mediatama Maxima Tbk (DMMX.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Fractyl Health, Inc. Common Stock (GUTS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fractyl Health, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- British American Tobacco p.l.c. (BATS.L) Income Statement Analysis – Financial Results
- CMIC Ocean En-Tech Holding Co., Ltd. (0206.HK) Income Statement Analysis – Financial Results
- PwrCor, Inc. (PWCO) Income Statement Analysis – Financial Results
- HUAXI Securities Co., Ltd. (002926.SZ) Income Statement Analysis – Financial Results
- Ichigo Inc. (ICHIF) Income Statement Analysis – Financial Results
Fractyl Health, Inc. Common Stock (GUTS)
About Fractyl Health, Inc. Common Stock
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 120.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 77.00K | 452.00K | 676.00K | 770.00K | 893.00K |
| Gross Profit | 43.00K | -452.00K | -676.00K | -770.00K | -893.00K |
| Gross Profit Ratio | 35.83% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 38.04M | 34.35M | 26.44M | 22.43M | 20.89M |
| General & Administrative | 0.00 | 15.03M | 10.49M | 6.53M | 9.03M |
| Selling & Marketing | 0.00 | -452.00K | -676.00K | -770.00K | -893.00K |
| SG&A | 12.84M | 14.58M | 9.82M | 5.76M | 8.14M |
| Other Expenses | 0.00 | 2.31M | -9.00K | -1.00K | 0.00 |
| Operating Expenses | 50.88M | 48.93M | 36.25M | 28.19M | 29.03M |
| Cost & Expenses | 50.96M | 49.39M | 36.93M | 28.96M | 29.92M |
| Interest Income | 1.26M | 797.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 1.44M | 1.50M | 635.00K |
| Depreciation & Amortization | 286.00K | 452.00K | 676.00K | 770.00K | 893.00K |
| EBITDA | -50.55M | -48.93M | -36.25M | -28.19M | -29.03M |
| EBITDA Ratio | -42,125.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -50.84M | -49.39M | -36.93M | -28.96M | -29.92M |
| Operating Income Ratio | -42,363.33% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -26.26M | 2.93M | -1.81M | -1.52M | -673.00K |
| Income Before Tax | -77.09M | -46.45M | -38.74M | -30.48M | -30.59M |
| Income Before Tax Ratio | -64,242.50% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -77.09M | -46.45M | -38.74M | -30.48M | -30.59M |
| Net Income Ratio | -64,242.50% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.98 | -0.98 | -0.81 | -0.64 | -0.64 |
| EPS Diluted | -1.98 | -0.98 | -0.81 | -0.64 | -0.64 |
| Weighted Avg Shares Out | 47.61M | 47.61M | 47.61M | 47.61M | 47.61M |
| Weighted Avg Shares Out (Dil) | 47.61M | 47.61M | 47.61M | 47.61M | 47.61M |
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
BURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced it will report financial...
Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
At DDG, Fractyl Health will present new clinical updates on its ongoing real-world registry study of Revita ® in patients with T2D in Germany At DDW, Fractyl Health will provide an oral presentation from its Rejuva ® platform with new...
The 3 Most Volatile Stocks for Short-Term Traders: April 2024
Volatile stocks are short-term traders' bread and butter. Making money both ways – whether the stock goes up or down – means that finding the most volatile stocks is the shortest path to fast cash opportunities for day traders and...
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced the appointment of Adrian...
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Received IDE approval for the Revita® Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 Based Drugs Completion of enrollment in pivotal Revitalize-1 study in patients with inadequately controlled T2D expected in second quarter of...
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March - Inspire Veterinary (NASDAQ:IVP), Fractyl Health (NASDAQ:GUTS)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
Fractyl Health today announced promising new preclinical findings for the first clinical candidate in its Rejuva® pancreatic gene therapy platform.
Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
Fractyl Health today announced promising new preclinical findings for the first clinical candidate in its Rejuva® pancreatic gene therapy platform.
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
LEXINGTON, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (“Fractyl Health” or the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of Type 2 Diabetes (T2D) and obesity, today announced the...
Source: https://incomestatements.info
Category: Stock Reports